Steady growth at BioAnalysis over the last three years has come from referrals rather than overt marketing efforts. Our customers appreciate that we take time to understand their needs with every project. In 2024 we heard a recurring call for BioAnalysis to include potency assays for our client’s gene therapy programs.

We are thrilled to announce that we will meet this need by mid-2025, following the buildout of additional lab space.

Potency assays will evaluate infectivity, transcription, translation, protein modification, and protein function. The Molecular Biology Lab will include cell culture capability, Enzyme-linked Immunosorbent Assays (ELISA – already operating in GMP), Digital Droplet Polymerase Chain Reaction (ddPCR), Flow Cytometry, and more!

Stay tuned for updates!